Showing 1581-1590 of 1679 results for "".
- Crescita Therapeutics Announces Management and Board Changeshttps://practicaldermatology.com/news/crescita-therapeutics-announces-management-and-board-changes/2458293/Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, introduced Ms. Muneerah Kanji, MBA, CPA, CA, Crescita's Corporate Controll
- Game Change: The New Global Psoriasis Atlas to Accrue Worldwide PsO Datahttps://practicaldermatology.com/news/game-change-the-new-global-psoriasis-atlas-to-accrue-worldwide-pso-data/2458419/Three global health organizations are joining forces to launch the Global Psoriasis Atlas (GPA), the first-ever worldwide database on psoriasis. The GPA project comes in response to the 2016 World Health Organization (WHO) Global Report on
- Cloudy with a Chance of Wrinkles: ROC Ranks US Cities By Wrinkle Indexhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-roc-ranks-cities-by-wrinkle-index/2458453/Philadelphia will be the most wrinkle-prone city in America come 2040 thanks to high stress levels, more airborne pollution, lengthy commute times and higher than average smoking rates, according to the 2016 RoC® Wrinkle Ranking. San Jose, Calif. will hold the least wrinkle-pron
- Fat Chance Teen Acne Doesn't Contain Diacylglycerolshttps://practicaldermatology.com/news/study-fat-chance-teen-acne-doesnt-contain-diacylglycerols/2458462/New research provides a fingerprint of the fats found in sebum, namely diacylglycerols. The findings appear in the Journal of Lipid Resea
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- Second Skin Gets Second Chancehttps://practicaldermatology.com/news/second-skin-gets-second-chance/2458572/A “second skin” polymer may temporarily protect and tighten skin, and smooth wrinkles. Scientists at MIT, Massachusetts General Hospital, Living Proof, and Olivo Labs developed the material, which could also be used to deliver drugs to help treat skin conditions suc
- Valeant Announces CEO Succession Plan And Changes To Board; Provides Accounting And Financial Reporting Updatehttps://practicaldermatology.com/news/valeant-announces-ceo-succession-plan-and-changes-to-board-provides-accounting-and-financial-reporting-update/2458640/Valeant’s board has initiated a search to identify a candidate to succeed J. Michael Pearson as chief executive officer (CEO). Mr. Pearson will continue to serve as CEO and a director until his replacement is appointed. The company also announced that William A. Ackman, CEO of Persh
- Cool Change: New CoolSculpting Apps Slash Treatment Timehttps://practicaldermatology.com/news/cool-change-new-coolsculpting-apps-slash-treatment-time/2458666/ZELTIQ® Aesthetics, Inc. is welcoming a new family of applicators called CoolAdvantage™ at the American Academy of Dermatology Annual Meeting in Washington, D.C. The CoolAdvantage applicator delivers CoolSculpting
- Valeant Pharmaceuticals Comments On Management Changehttps://practicaldermatology.com/news/valeant-pharmaceuticals-comments-on-management-change/2458668/Valeant Pharmaceuticals International, Inc. today issued the following comments in response to inquiries from investors regarding Deb Jorn's departure from Valeant.
- Pfizer Outlines Post-Allergan Deal Leadership Team Changeshttps://practicaldermatology.com/news/pfizer-outlines-post-allergan-deal-leadership-team-changes/2458709/Brent Saunders will become President and Chief Operating Officer of the combined Pfizer and Allergan company following the close of the merger deal. In this role, he will over see Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions. The c